Synthetic Biologics is developing cutting-edge therapeutics to treat pathogen-specific diseases.
Our two leading candidates are:
SYN-004 (ribaxamase) to prevent C. difficile infection and antibiotic-associated diarrhea
SYN-010 to treat irritable bowel syndrome with constipation (IBS-C)
We are a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. Founded in 2001, Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN".
-- Conference Call Scheduled for Tuesday, November 1, 2016 at 8:30 a.m. EDT -- ROCKVILLE, Md., Oct. 25, 2016 /PRNewswire/ --